Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Symptomer fra mundhulen

    Research output: Chapter in Book/Report/Conference proceedingCompendium/lecture notes chapterEducationpeer-review

  3. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment

    Research output: Contribution to journalReviewResearchpeer-review

  4. Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Morten Schiodt
  • Saroj Vadhan-Raj
  • Mark S Chambers
  • Ourania Nicolatou-Galitis
  • Constantinus Politis
  • Ruxandra Coropciuc
  • Stefano Fedele
  • Danielle Jandial
  • Jeffrey Zhang
  • Haijun Ma
  • Deborah P Saunders
View graph of relations

PURPOSE: This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate.

METHODS: Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at baseline and every 3 months for 2 years and then every 6 months for 3 years until death, consent withdrawal, or loss to follow-up. The primary endpoint was the rate and time course of ONJ resolution. Secondary endpoints included frequency of incident ONJ risk factors, ONJ treatment patterns, and treatment patterns of antiresorptive agents for subsequent ONJ.

RESULTS: Overall, 327 patients were enrolled; 207 (63%) were continuing on study at data cutoff. Up to 69% of evaluable patients with ONJ had resolution or improvement during the study. ONJ resolution (AAOMS ONJ staging criteria) was observed in 114 patients (35%); median (interquartile range) time from ONJ onset to resolution was 7.3 (4.5-11.4) months. Most patients (97%) had received antiresorptive medication before ONJ development, 9 patients (3%) had not; 68% had received zoledronic acid, 38% had received denosumab, and 10% had received pamidronate (56% had received bisphosphonates only, 18% had received denosumab only, and 21% had exposure to both).

CONCLUSIONS: These results are consistent with those observed in clinical trials evaluating skeletal-related events in patients with advanced malignancy involving bone. Longer follow-up will provide further information on ONJ recurrence and resolution rates between medically and surgically managed patients.

Original languageEnglish
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Issue number6
Pages (from-to)1905-1915
Number of pages11
Publication statusPublished - Jun 2018

ID: 56437778